Navigation Links
Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
Date:6/27/2011

olerated dose of escalating doses of SGX201, as well as the preliminary efficacy of SGX201 of the four dose groups for prevention of signs and symptoms of acute radiation enteritis.  So far in the trial, SGX201 appears to be safe and well tolerated in all dose groups.  Complete results from this clinical trial are expected to be announced in the fourth quarter of 2011. This study has been supported in large part by a two-year Small Business Innovation Research (SBIR) grant award, which provided Soligenix with approximately $510,000 in non-dilutive funding.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a $1.2 million FDA Orphan Products Grant-supported confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD. Soligenix is also conducting a National Cancer Institute (NCI)-supported Phase 1/2 clinical trial of SGX201 in the prevention of acute radiation enteritis. Additionally, Soligenix has a Lipid Polymer Micelle (LPM™) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, Soligenix is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense product in development is a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax™ has been shown to
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
2. Soligenix to Present at 13th Annual BIO CEO & Investor Conference
3. Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
4. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
5. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
6. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
7. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
10. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
11. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
(Date:8/3/2015)... 2015 /OFF HOLD OFF ... PIV757417 The following release: "Biotech Advancements Coupled with ... & Treatments for Critical-Care Patients With Severe Wound ... Aug 2015 12:30 GMT Cooperative research ... research and top-tier universities for identifying biotech solutions ...
(Date:8/3/2015)... BioPharma Inc. (NASDAQ: ARRY ) today reported ... of its fiscal year ended June 30, 2015. ... noted, "Binimetinib and encorafenib, two innovative oncology products ... submissions in 2016. Additional data shared over the ... further validate the value of these programs by ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
... (Nasdaq: ARNA ) today announced positive preliminary ... in patients with chronic insomnia. APD125,is an orally ... being,evaluated in insomnia patients who have difficulty maintaining ... patients treated with APD125,experienced statistically significant improvements in ...
... N.J., Sept. 25 DOV Pharmaceutical,Inc. ("DOV", or ... additional Phase Ib results for DOV 21,947, its ... depression and obesity. A,preliminary analysis of the study ... at the doses examined, and produced a statistically,significant ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 2Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 3Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 4Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 5Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 6Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 7DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 2DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 3DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 4DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study 5
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... According to an opinion ... calories out of person’s diet leads to one pound of weight loss may not be ... caloric reduction that translates to one pound of fat varies – based both on the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt ... from the University of Pittsburgh School of Medicine are leading a five-year, $5 ... in sub-Saharan Africa. , A cooperative agreement awarded by the U.S. Agency ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... online retailer of nutritional supplements, has officially opened the polls for their ... in the following categories:, ,     Brand of the Year ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... ® and Navigant Center for Healthcare Research and Policy Analysis show widespread support ... of respondents said they agreed or strongly agreed that the controversial law passed ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from USA ... recent years, according to the American Dental Association. According to a study by the ... from 1.1 million in a single year to 2.2 million a year. Dentists and ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3
... via flexible, secure 4 Gigabit network ... by 98 percent, PORTLAND, Ore., May 22 ... provider of managed voice and data,networking solutions for businesses, ... The Oregon Clinic,s West,Hills Gastroenterology and West Side Surgical ...
... swallowing ... difficulties, MINNEAPOLIS, ... Nutrition is bringing visibility to,dysphagia -- an often undiagnosed, secondary condition ... health,problem that makes swallowing extremely difficult and can lead to dangerous,health ...
... Annual ... Conference, ... non-profit 501(c)(3) organization, today announces the,opening of the public comment period ... ends on,July 7, 2008., Thomas Wilson, PhD, DrPH, PHII Co-Founder ...
... Researchers analyze different proteins in progression of risk factors ... -- New insights into lung disease and lung function ... , The researchers analyzed data from the U.S. National ... Development in Young Adults) observational cohort, which recently completed ...
... WORCESTER, Mass.Today, Advanced BioScience Laboratories, Inc. (ABL) and ... that their unique HIV vaccine formulation was effective ... healthy human volunteers. The findings are published ... immune responses induced by a polyvalent DNA primeprotein ...
... that in the dog-eat-dog, look-out-for-No. 1, highly competitive business ... to succeed as an entrepreneur. That statement may sound ... A team led by a University of Missouri researcher ... and women decide to pursue entrepreneurship as a viable ...
Cached Medicine News:Health News:The Oregon Clinic Extends Patient Care Services Across Metro Portland with Time Warner Telecom's Metro Ethernet Service 2Health News:The Oregon Clinic Extends Patient Care Services Across Metro Portland with Time Warner Telecom's Metro Ethernet Service 3Health News:Stroke Victims Often Suffer From Lack of Nutrients With Undiagnosed Disorder 2Health News:Stroke Victims Often Suffer From Lack of Nutrients With Undiagnosed Disorder 3Health News:Population Health Impact Institute Releases Methods Evaluation Process(TM) (MEP(TM)) Accreditation Standards for Public Comment Period 2Health News:CARDIA Studies Open Window on Heart, Lung Diseases 2Health News:CARDIA Studies Open Window on Heart, Lung Diseases 3Health News:Study finds unique HIV vaccine formula elicits strong immune responses 2Health News:Study finds unique HIV vaccine formula elicits strong immune responses 3Health News:Taking care of business shouldn't be just for men 2
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... HumaPen MEMOIR is the first and only insulin pen ... and amount of your last 16 doses (including priming ... insulin you last took. With HumaPen MEMOIR, you simply ... one-unit increments (up to 60 units) after initial set-up. ...
PulmoLife is a new COPD screening device, designed for quick and easy screening of adult smokers for early detection of COPD....
Medicine Products: